Danaher Corporation
DHR · What the business does, what can go wrong, and how options sellers approach it
What it does
Danaher is a life sciences and diagnostics company. It makes instruments, consumables, software and services used by scientists, drug developers, hospitals and laboratories.
Its main business lines include life sciences tools (equipment and materials used to research and discover new therapies), diagnostics (testing systems used in clinical labs and hospitals), and biotechnology products (including the filters, resins and related materials used to make biologic medicines).
How it makes money
Danaher sells equipment, but much of its appeal comes from recurring revenue. After a customer installs an instrument, they usually keep buying the reagents, test kits, filters and other consumables that run on it, and often pay for service contracts too.
The company is also known for the Danaher Business System, a set of continuous-improvement methods it applies to its operations and to the businesses it acquires.
Why investors own it
- Recurring consumables and service revenue can make results steadier than a pure equipment seller.
- Exposure to long-term demand for biologic drugs, vaccines and diagnostic testing.
- A long record of buying businesses and improving how they operate.
- Generally strong cash generation, which funds acquisitions and reinvestment.
What can go wrong
- Demand from biopharma customers can swing with funding conditions, drug pipelines and inventory cycles.
- Diagnostic testing volumes can fall sharply when a surge in demand, such as a pandemic, fades.
- Acquisitions can be expensive and may not deliver the expected benefits.
- Healthcare and laboratory budgets, regulation and pricing pressure can all affect results.
What to watch
- Core revenue growth (excluding acquisitions and currency)
- Bioprocessing order trends and customer inventory levels
- Diagnostics demand and testing volumes
- Operating margin
- Free cash flow conversion
- Management guidance and any portfolio changes
- Interest rates and biotech funding conditions
Options income angle
Options on DHR are typically liquid for a large-cap stock, with many strikes and expirations available.
Implied volatility tends to rise ahead of quarterly earnings and when guidance or biopharma demand comes into question. It can also move with swings in biotech sentiment.
A caution for premium sellers: a sharp move after earnings or a guidance change can quickly overwhelm the premium collected. Covered calls can cap gains, and short puts can leave you buying shares after a drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Danaher grew sales modestly in 2025, but net earnings from continuing operations fell because of large intangible asset impairments, mostly in Life Sciences. The filing also flags a pending acquisition of Masimo Corporation that the company expects to partly fund with debt. It names tariffs, China pricing policy and weak biotech funding as the main outside pressures.
How the business did
- Overall revenues increased 3.0% and core sales increased 2.0%. Core sales exclude acquisitions and currency translation. Net earnings from continuing operations were approximately $3.6 billion, or $5.03 per diluted common share, versus approximately $3.9 billion, or $5.29, in 2024.
- Operating profit margin decreased 130 basis points (a basis point is one hundredth of a percentage point) from 20.4% to 19.1%. Impairment charges accounted for 120 basis points of that.
- Biotechnology sales were $7,293 million, with core sales up 6.5%, led by bioprocessing consumables. Life Sciences sales were $7,334 million, with core sales down 1.5% and operating profit of $520 million versus $879 million in 2024. Diagnostics sales were $9,941 million, with core sales up 1.5% despite price decreases in China.
- Operating cash flows from continuing operations were $6,416 million. The company paid $3,088 million for share repurchases versus $5,979 million in 2024, paid $878 million in dividends, and paid no cash for acquisitions.
- Incremental tariff costs were less than $300 million, which the company says it largely offset with footprint changes, surcharges and cost savings.
Risks specific to this company
- Masimo deal and debt: The company expects to borrow to pay part of the Masimo price, and the deal still needs antitrust and other approvals. Debt was approximately $18.4 billion at year end, and credit facilities include a leverage ratio requirement.
- China: China was approximately 11% of sales. A volume-based procurement program lowers prices there, and Diagnostics core sales in China declined.
- Impairments: Goodwill and other intangibles carried a net value of approximately $61.0 billion. One reporting unit with a carrying value of approximately $10.1 billion had fair value only 20% above carrying value in the annual test.
- Life Sciences demand: Lower funding at emerging biotech and academic customers hurt sales. Two large customers also bought fewer plasmids and mRNA products.
- Tariffs: The Supreme Court ruled in February 2026 that IEEPA does not authorize the tariffs imposed under it. The administration plans new tariffs under other authority, and the company calls the full impact uncertain.
- Tax disputes: Danish authorities assessed approximately DKK 2.1 billion for 2004 through 2015, which the company is appealing. Separately, the spin-offs of Fortive, Envista and Veralto could become taxable if the IRS disagrees with the tax opinions the company obtained.
What management is watching
- 2026 assumptions: Bioprocessing growth similar to 2025, a modest improvement in Life Sciences end markets, and higher Diagnostics growth as the company moves past the peak of China policy headwinds.
- Respiratory season: Some second-half 2025 test demand came from customers stocking up, so a milder season could hurt demand.
- Tax rate: The company expects a 2026 effective tax rate of approximately 17.0%, up from 15.0% in 2025.
- Spending: R&D was $1,598 million. Management describes significant investments in technology, AI and manufacturing, plus continued productivity improvement actions.
- Currency and measures: A stronger U.S. dollar in 2026 would hurt sales and results. Management points investors to core sales, a non-GAAP measure that also feeds executive incentive pay.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 25, 2026, filed October 21, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Danaher's sales rose 8.5% in the third quarter of 2026, but core sales (sales excluding acquisitions, currency and tariff refunds returned to customers) rose only 3.0%. Most of the growth came from the Masimo acquisition, completed June 10, 2026 for approximately $9.8 billion in cash. Net earnings from continuing operations were approximately $1.2 billion, or $1.71 per diluted share, helped by a $263 million one-time tax benefit.
How the business did
- Sales: The quarter's sales were $6,554 million, against $6,053 million a year earlier. Core sales excluding respiratory testing grew 5.5%, with all three segments higher. Respiratory test demand fell on lower prevalence of respiratory disease. Price decreases of 0.5% held back growth.
- Profit: Operating profit margin was 19.0%, against 19.1% a year earlier. A Masimo inventory fair value adjustment cost 130 basis points (a basis point is one hundredth of a percentage point). Year to date, net earnings from continuing operations were approximately $3.1 billion, or $4.38 per diluted share, against $3.37 a year earlier, which included impairment charges.
- Segments: Biotechnology core sales rose 5.0% and Life Sciences 4.5%. Diagnostics sales rose 17.0%, mostly from Masimo, while its core sales rose 0.5% (7.0% excluding respiratory testing). Diagnostics operating margin fell to 21.3% from 27.0%. High-growth markets saw core sales up 10%, with high-single digit growth in China.
- Cash and capital: Nine-month operating cash flow was $4,742 million, against $4,299 million. The company paid $9,881 million for acquisitions, mostly by borrowing, and interest expense for the quarter was $135 million. It paid $790 million in dividends and repurchased $894 million of stock, against $3,088 million a year earlier. It held approximately $5.7 billion in cash.
- Unusual items: After the Supreme Court ruled against certain IEEPA tariffs, the company began receiving refunds and returning part to customers, which reduced reported sales by 1.0%. The net earnings effect of the refunds, after those customer refunds, was less than $100 million.
What management is watching
- The severity of the upcoming respiratory season, and customer purchases made ahead of it, could hurt respiratory test demand over the rest of 2026.
- The company expects a full-year 2026 effective tax rate of approximately 17.0%.
- The Middle East conflict has caused delivery delays and higher logistics costs. Management says continued or worsened conflict could raise those costs and weigh on demand. The timing and extent of further tariff refunds and the impact of new tariffs remain uncertain.
- Management points investors to core sales and core sales excluding respiratory testing. Beginning with this report, core sales also excludes tariff refunds to customers. Research and development spending was 6.6% of sales, reflecting new product development.
Follow DHR in Kortex
The Kortex app shows DHR's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.